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Rhabdomyosarcoma (RMS) is the most common malignant soft tissue tumor in children and is highly resistant to all forms of
treatment currently available once metastasis or relapse has commenced. As it has recently been determined that the acetylcholine
receptor (AChR) γ-subunit, which defines the fetal AChR (fAChR) isoform, is almost exclusively expressed in RMS post partum, we
recombinantly fused a single chain variable fragment (scFv) derived from a fully human anti-fAChR Fab-fragment to Pseudomonas
exotoxin A to generate an anti-fAChR immunotoxin (scFv35-ETA). While scFv35-ETA had no damaging effect on fAChR-negative
control cell lines, it killed human embryonic and alveolar RMS cell lines in vitro and delayed RMS development in a murine
transplantation model. These results indicate that scFv35-ETA may be a valuable new therapeutic tool as well as a relevant step
towards the development of a fully human immunotoxin directed against RMS. Moreover, as approximately 20% of metastatic
malignant melanomas (MMs) display rhabdoid features including the expression of fAChR, the immunotoxin we developed may
also prove to be of significant use in the treatment of these more common and most often fatal neoplasms.
1. Introduction
Three forms of RMS are recognized, each of which shows
skeletal muscle differentiation, but are distinguished by other
genetic and biological characteristics: (1) embryonal RMS,
characterized by loss of heterozygosity at 11p15; (2) the
more aggressive alveolar RMS, often accompanied by Pax3
or Pax7-FKHR gene fusions resulting from translocations
t(2;13) (q35; q14) and t(1; 13) (p36; q14), respectively; and
(3) the rare pleomorphic RMS, which is genetically complex
and tends to occur in adults [1]. As a group, RMS is the
most frequent soft tissue tumor in children [2]. Metastatic
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alveolar RMS in children older than 10 years as well as
relapse of disease tends to be refractory to all current forms
of therapy including adjuvant bone marrow transplantation
[3], resulting in 5-year survival rates of no more than 5–
20% [2–4]. Therefore, novel first line or adjuvant treatment
strategies are urgently needed for high-risk RMS patients [5].
As we have previously shown that, after birth, the fetal AChR
(fAChR) is almost exclusively expressed in RMS [6–8] and
that anti-fAChR chimeric T-cells could kill fAChR-positive
RMS cell lines in vitro [9], this target seemed promising for
the development of an immunotoxin, a molecule consisting
of a toxin coupled to an antibody fragment designed to
destroy a specific type of cell [10]. Therefore, we generated
an immunotoxin targeting fAChR in order to exploit its
expression pattern for the treatment of RMS.
The nicotinic Acetylcholine Receptor (AChR) is a pen-
tameric ion channel which appears in an embryonic (fAChR)
and an adult isoform (AChR). Both isoforms comprise
two α, one β, and one δ subunits, while the γ-subunit is
specific for fAChR. In the process of muscle innervation
during embryonic development, the γ-subunit is replaced
by an ε-subunit, leading to the replacement of fAChR by
AChR. After birth, expression of fAChR is restricted to
few tissue forms including extraocular muscle fibers of
unknown function [11–13], thymus myoid cells [14–16],
and skeletal muscles following denervation [17, 18]. In
contrast, the vast majority of human embryonic and alveolar
rhabdomyosarcomas strongly express fAChR on the tumor
cell surface [6–8], making this receptor ideal for immune-
targeting by an immunotoxin.
Several disorders involving the immunization against
fAChR shed light on the molecular mechanisms of anti-
fAChR antibodies. In myasthenia gravis (MG), an autoim-
mune disease most commonly caused by the appearance
of anti-AChR autoantibodies [19], the majority of patients
develop autoantibodies against AChR as well as fAChR [19,
20]. In studies of MG, it has been shown that anti-AChR
autoantibodies are internalized along with AChR after bind-
ing, which is a necessary mechanism for an immunotoxin
against RMS to exert its effect on target cells [19]. The
unborn children of parous pregnant women who developed
autoantibodies against fAChR can develop arthrogryposis
multiplex following diaplacentar passage of these antibodies,
while their mothers remain free of symptoms. This not only
shows that the γ-subunit of fAChR harbors immunologically
specific epitopes that are potentially suitable as target for an
immunotoxin in the therapy of RMS but also suggests that
the use of an anti-fAChR immunotoxin in RMS treatment
is unlikely to induce serious side effects [21]. Finally, cDNA
libraries derived from MG patients and mothers of children
suffering from arthrogryposis multiplex should be ideal
sources for the generation of fAChR-antibodies in vitro.
This report is the first description of the cloning, expres-
sion and functional testing of an immunotoxin targeting
the AChR γ-subunit. The immunotoxin consists of an scFv
antibody fragment derived from a human combinatorial
thymus cDNA library prepared from a woman producing
autoantibodies against fetal AchR [21] and a truncated
version of the pseudomonas exotoxin A. This toxin killed
RMS cells in vitro and delayed tumor growth in a murine
transplantation model.
2. Results
2.1. An Immunotoxin Targeting theMain Immunogenic Region
(MIR) of the AChR α-Subunit Kills RMS Cells In Vitro.
Initially, we generated an immunotoxin containing ETA
based on a recombinant single chain Fv fragment derived
from the rat monoclonal antibody mAb192 against the main
immunogenic region (MIR) of the human AChR α-subunit
[22, 23]. This model immunotoxin (scFv192-ETA) bound
to several RMS cell lines and killed the RMS cell lines
TE-671, FL-OH-1 and RD in a dose-dependent manner,
while fAChR-negative RMS and non-RMS hematopoietic
control cell lines (A-204, U937) were killed only at much
higher immunotoxin concentrations (not shown). These
experiments showed that an immunotoxin targeting AChR
is able to kill AChR-positive RMS cells in vitro while leaving
AChR-negative cell lines relatively unharmed.
2.2. Construction and In Vitro Characterization of Immuno-
toxins Targeting the γ-Subunit of Human Fetal AChR. Subse-
quently, we generated an ETA-based immunotoxin targeting
the AChRγ-subunit, which is specific for the fetal form of
the AChR. Two recombinant human Fab fragments (Fab35
and Fab38) were isolated from a combinatorial cDNA library
derived from the thymus of a seropositive MG patient
with high titers of anti-AChR γ-subunit antibodies [21].
Although the two Fab fragment cDNAs were inserted in-
frame into the ETA-vector, they were translated inefficiently
in E. coli BL21DE3, resulting in several abnormal protein
fragments of 70–80 kDa instead of the expected 120 kDa
full-length product (not shown). Therefore, we used the
Fab35 and Fab38 cDNAs to produce single-chain Fv (scFv)
fragments by overlap extension PCR (Figure 1). VH and VL
fragments were linked by a 36-nucleotide (glycine/serine)
spacer to produce scFv fragments with a VH-VL and a VL-
VH orientation from both Fabs, yielding four different scFvs.
The four scFv cDNAs were inserted into the ETA vector
pBM-1.0, checked for proper ligation by sequencing and
expressed in E. coli BL21DE3. The resulting immunotoxins
were purified and the binding capacity to RMS cells was
determined by flow cytometry. Of the four molecules
examined, only the Fab35 derivative scFv35/VL-VH-ETA
specifically bound to cells of the fAChR-positive embryonal
RMS cell lines TE-671, RD, and FL-OH-1 as well as to
the alveolar RMS cell lines RH-30 and Ax-OH-1 and while
showing virtually no reactivity with the fAChR-negative
control RMS line A-204 or the hematopoietic cell line U937
(Figure 2).
This immunotoxin, termed scFv35-ETA, killed fAChR-
positiveRMS cell lines in a dose-dependent manner, while
it had almost no effect on the control cell lines A-204 and
U937 (Figures 3(a) and 3(b)). Specificity of the growth
inhibitory effect was demonstrated using a nonbinding
control composed of a non-binding scFv fused to ETA
(mock-ETA). The IC50 values of scFv35-ETA and the control
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Table 1: Comparison of IC50 values of scFv35-ETA and mock-ETA control on various cell lines.
Mean IC50 (nM)
TE-671 RD FL-OH-1 Ax-OH-1 RH-30 U937 A-204
scFv35-ETA 34 1.5 0.13 14 113 >500 >500
mock-ETA 113 22 12 90 >500 >500 >500
IC50 values indicating concentrations required to achieve a 50% reduction of protein synthesis relative to untreated control cells as derived from colorimetric
XTT assay in Figure 3.
Sfi I 1
2 Linker
3Linker
4 NOT I
VII5′-PCR-sense primer with integrated Sfi I site at the 5′ end
VII3′-PCR-antisense primer with overhanging 36 nt. glycine/serine linker at the 3′ end
VL5′-PCR-sense primer with overhanging 36 nt. glycin/serin linker at the 5′ end
VL3′-PCR-antisense primer with integrated NOT I site at the 3′ end
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Figure 1: Schematic presentation of the synthesis of scFv fragments based on the recombinant Fab fragments Fab35 and Fab38 [21] using
overlap extension PCR.
immunotoxin on the tested cell lines are summarized in
Table 1. The inhibitory effect could be significantly enhanced
using the fAChR-specific scFv35-ETA as shown by a decrease
of IC50 values ranging from 3 (TE-671) to 100-fold (FL-OH-
1). Furthermore, addition of 100-fold molar excess of free
scFv35 in a competitive approach could completely knock-
down the toxic effect of scFv35-ETA fusion protein emp-
hazising its specificity (Figure 3(c)). To further characterize
the toxic effect of scFv35-ETA on RMS cells, an annexin V-
based apoptosis assay was performed on embryonal RMS cell
line RD. The amount of cells staining positive for annexin V,
an early apoptosis marker, clearly increased during the time
points of 12, 14, and 48 hours of incubation. Finally, after 48
hours a total of 51,7 % of cells incubated with scFv35-ETA
stained positive for annexin V compared to 9.28 in the PBS
control (Figure 4).
2.3. The γ-Subunit-Specific Immunotoxin Delays Tumor
Development in a Mouse RMS Transplantation Model. The
in vivo toxicity of scFv35-ETA against RD RMS cells was
tested in a murine RMS transplantation model [24]. Initial
tests on healthy SCID mice revealed that intraperitoneal
injection of 10 μg scFv35-ETA per mouse (n = 10) had
no apparent adverse effects on mobility, weight gain, or
survival (up to 60 days). Therefore, this dose was used in
concert with the subcutaneous injection of 5 × 106 RD cells
per mouse (n = 10), with saline injections as controls
(n = 4). Twice daily injections of 10 μg scFv35-ETA per
mouse were repeated up to day 10. Tumor development was
monitored by daily inspection and palpation. As shown in
Figure 4, 100% of mock injected mice developed palpable
tumors by day 7 of the experiment and clearly visible
subcutaneous tumors by day 10 (volume: 59 +/− 9 mm3).
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Figure 2: FACS Analysis of scFv35-ETA.
In contrast, the mice injected with the immunotoxin showed
little evidence of tumor development by day 7 and no
visible sign of subcutaneous tumor development by day
10, although smaller tumors could be palpated (volume:
8 +/−27 mm3). Until day 12, the tumors in the treated
group were significantly smaller than those in the controls.
After finishing the course of daily immunotoxin injections,
however, subcutaneous tumors began to enlarge rapidly in
the test group and reached the same size as the tumors in the
control group by day 14 (Figure 4).
3. Discussion
In our study, which involved the development of an
immunotoxin against RMS, we report three major new
Journal of Biomedicine and Biotechnology 5
V
ia
bi
lit
y
(%
)
0
10
20
30
40
50
60
70
80
90
100
110
120
scFv35-ETA (nM)
10−6 10−5 10−4 10−3 10−2 10−1 100 101 102 103
RD
TE-671
FL-OH-1
Ax-OH-1
RH-30
(a)
V
ia
bi
lit
y
(%
)
0
10
20
30
40
50
60
70
80
90
100
110
120
scFv35-ETA (nM)
10−6 10−5 10−4 10−3 10−2 10−1 100 101 102 103
U937
A-204
(b)
V
ia
bi
lit
y
(%
)
0
10
20
30
40
50
60
70
80
90
100
110
scFv35-ETA
1.5 nM
scFv35
150 nM
C 1.5 nM C 15 nM C 150 nM
(c)
Figure 3: Colorimetric XTT cytotoxicity assays with various immunotoxin concentrations (n = 3 parallel cell cultures per dilution) showing
strong dose-dependent toxicity of the immunotoxin scFv35-ETA directed against the acetylcholine receptor (AChR) γ-subunit on positive
RMS cell lines TE671, RD, and FL-OH-1, RH-30 and Ax-OH-1 even at higher dilutions (a). Lower to no toxicity of the immunotoxin were
observed towards the control cell lines A-204 and U937 not expressing fAChR (b). Competition of toxicity could be achieved with 1–100-fold
molar excess (C 1.5–150 nM) of scFv35 added to cells incubated with 1.5 nM scFv35-ETA, whereas scFv35 alone does not inhibit cell growth
even at 100 fold higher concentration (c). Cell viability is expressed as percentage inhibition of cell proliferation compared to non-treated
cells.
findings: (1) we showed that the major immunogenic
region of the nicotinic AChR α-subunit can be used as an
immunotoxin target to kill RMS cells in vitro, (2) we were
able to generate a human scFv autoantibody fragment that
binds to the AChR γ-subunit of human RMS cell lines, and
(3) a recombinant ETA-based immunotoxin derived from
this antibody fragment killed human RMS cells in vitro and
significantly delayed tumor development in a mouse RMS
transplantation model, although it alone was insufficient to
cure the disease.
Antibody-based immunotherapy is a well-established
method in the treatment of various tumor types, such as
ErbB2-positive breast cancer [25], Hodgkin lymphoma [26–
30], acute myeloid leukemia [31–33], colon cancer [34,
35], lung cancer [36], melanoma [37], and neuroblastoma
[38–40]. However, immunotoxin therapy has not yet been
applied to RMS, as an antigen expressed specifically and at
high levels on the surface of these tumor cells was not known
until recently [9]. This obstacle was overcome when we
found that the fetal AChR isoform (fAChR) is expressed on
the surface of the vast majority of RMS cells, while it is absent
from normal innervated muscles [6, 9, 18]. Recently, we
showed that anti-fAChR chimeric T-cells could kill fAChR-
positive RMS cell lines in vitro while fAChR-negative cells
remained unharmed [9]. However, chimeric T-cells based
on antibody fragments linked to T-cell receptor subunits
(such as the ζ-chain) are notoriously susceptible to deletion
and anergy in vivo [41], suggesting that an immunotoxin
specific for the same epitope would be a more promising
approach.
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Figure 4: Annexin V apoptosis assay on RD cells incubated with either scFv35-ETA or PBScontrol for 12, 14 and 48 hours. Quadrants
distinguish viable cells (lower left), early apoptotic cells (lower right), late apoptotic cells (upper right) and necrotic cells (upper left).
Numbers indicate percentage of early and late apoptotic cells, respectively.
Therefore, we set out to generate an immunotoxin to
target fAChR by first expressing a fusion protein between
an anti-AChR antibody fragment and the Pseudomonas
exotoxin A (scFv192-ETA). In these experiments, we found
proof that scFv192-ETA kills RMS cells in vitro, while
leaving AChR-negative control cell lines relatively unharmed.
These data also show that fusion of scFv192 to a truncated
Pseudomonas exotoxin A and expression in bacteria has
no detrimental effect on the binding specificity of the
rat antibody fragment [22]. Subsequently, we constructed
immunotoxins specific for the AChR γ-subunit by using
two recombinant human Fab fragments (scFv35 and scFv38)
known for their specificity and strong affinity for the γ-
subunit of the AchR [21] and generated four different scFv
derivatives. A human antibody fragment was chosen firstly
as there are no easily available well-characterized mouse or
rat monoclonal antibodies with γ-subunit specificity and
secondly because human anti-AChR autoantibodies from
MG patients are known for their high affinity and specificity,
properties that are often conserved in recombinant Fab
or single chain Fv derivatives [22, 42, 43]. Furthermore,
human monoclonal autoantibody fragments are preferable
as immunotoxin components as they are less likely to be
immunogenic than their rodent counterparts and could
pave the way towards the development of a fully human
immunotoxin using a human toxin component such as
a ribonuclease [28] or an effector such as an interleukin
[44]. Surprisingly, only one of the immunotoxins generated
(scFv35-ETA) showed significant binding to cell lines with
abundant, surface-displayed fetal AChR. As myasthenia
gravis autoantibodies critically depend on the 3-dimensional
conformation of their binding sites on several AChR subunits
[45], it is likely that steric hindrance prevented efficient
binding of the three unsuccessful variants. ScFv35-ETA was
cytotoxic to RMS cells both in vitro (Figures 3 and 4) and in a
pilot in vivo mouse model (Figure 5). For the efficacy studies
cell lines from both embryonal and alveolar subtype were
chosen that have all previously been shown to express fAChR
on the cell surface, indicating the responsiveness of both
subtypes to scFv35-ETAe. The specificity of scFv35-ETA was
confirmed in vitro by the lack of toxicity in control cells not
expressing fAChR and by competition of toxicity with scFv35
alone as well as in vivo in the 10 mice administered 20 μg
immunotoxin per day. This was not surprising, as carriers
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Figure 5: In vivo effect of scFv35-ETA on RD embryonal RMS cells
(5 × 106 RD cells per mouse) transplanted subcutaneously into
SCID mice. The first intraperitoneal immunotoxin injection (10 μg
twice daily) was carried out 2 days after the injection of tumor cells
and repeated daily until day 10.
of autoantibodies against fAChR are generally completely
asymptomatic [21], although it is known that, after birth,
fAChR is expressed in certain extraocular muscle fibers [12],
thymic myoid cells [14], and skeletal muscles following
denervation [17, 18].
However, the “single agent” in vivo treatment of mice
with scFv35-ETA for 10 days did not cure the animals,
as tumor growth was significantly delayed but not totally
blocked as long as the immunotoxin was administered and
progressed rapidly after the end of treatment. Among the
known mechanisms leading to immunotoxin resistance, the
poor vascularization of sarcomas [37, 46] is the most likely
reason for this shortfall in therapeutic efficacy. However, this
could be addressed by dose elevation as well as prolonged
administration, an approach in which the use of a fully
human immunotoxin may be necessary to circumvent
sensitization against a mouse, rat, or humanized antibody
component [37, 46].
In addition, other strategies to improve the treatment
of RMS using scFv35-based immunotoxins can be envis-
aged. First, there are well-established techniques to stabilize
immunotoxins [47], increase their affinity [47], and improve
their uptake into tumor cells [48]. Second, as shown in
leukemia [49], the therapeutic effect of immunotoxins can
be improved when the expression level of the target antigen
and the percentage of target-positive tumor cells are ele-
vated pharmacologically. Third, single-agent antibody-based
therapies can be made more efficient when combined with
traditional chemotherapies or the targeted application of
cytokines, chemokines, antiangiogenic agents, or modifiers
of degradation pathways that inactivate toxins [44, 50–
59]. Any or all of these strategies could be applied to
the treatment of RMS using scFv35-ETA. For example, it
has previously been shown that chemotherapy can induce
the differentiation of immature, AChRlow RMS cells to
more mature rhabdomyoblasts with increased expression
of muscle specific proteins including fetal AChRs [9, 60].
Thus, the synchronous or metachronous application of
chemotherapy and scFv35-ETA could be more successful
in treating RMS than scFv35-ETA alone. However, further
preclinical trials are needed to substantiate whether any of
the strategies described above actually have a positive impact
on the efficacy of RMS treatment using scFv35-ETA.
In summary, we have shown that the fetal AChR is a
specific marker of human RMS that can be recognized by
a scFv-based immunotoxin (scFv35-ETA). Our experiments
showed that the immunotoxin, the first sarcoma-directed
agent based on a fully human autoantibody fragment
described so far, was effective both in vitro and in vivo
against RMS cells and is therefore a promising candidate for
further preclinical development. This would include the use
of more refined murine RMS transplantation models using
a broad spectrum of RMS cell lines as well as molecular
modification of the immunotoxin for better stability and
higher binding affinity in vivo as well as the coupling of
the immunotoxin to human toxins or alternative effectors.
Finally, our recent observation that a subgroup of metastatic
malignant melanomas (MMs) can transdifferentiate into
fAChR-expressing RMS-like cells [61] suggests that a refined
fAChR-directed immunotoxin may also be of significant use
in the treatment of these tumors and may therefore have a
broader spectrum of therapeutic indications than anticipated
so far.
4. Methods
4.1. Generation of Anti-AChR Fab and scFv Fragments. The
cloning and expression of the high-affinity rat scFv192
fragment derived from the rat anti-AChR antibody mAb192
specific for the α67–76 sequence (main immunogenic region,
MIR) has been described previously [22]. The generation
of the recombinant human Fab fragments Fab35 and
Fab38 using a combinatorial cDNA thymus library from a
patient with thymic lymphoid hyperplasia and production of
autoantibodies specific for the anti-AChR γ-subunit has also
been described [21]. Fab35 and Fab38 were used to produce
scFvs by overlap extension PCR as shown in Figure 1. In
detail for the production of VH-VL scFvs from Fab35 and
Fab38 primers were used as indicated in Figure 1. By contrast
for VL-VH orientation of the scFvs the VL primers harboured
the SfiI site at the 5
′
end and the glycin/serin linker at the 3
′
end, whereas the VH primers had the glycin/serin linker at
the 5
′
end and the NotI site at 3
′
end. The primers are listed
in Table 2.
4.2. Production and Purification of the Immunotoxins. The
protocol for the production and purification of recombinant
immunotoxins was published previously [62]. Briefly, E. coli
strain BL21DE3 pLysS (Stratagene, Heidelberg, Germany)
was transformed with the corresponding plasmids and single
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Table 2
Primers for scFv from Fab35/38 in orientation VH-VL
scFv/Fab35 VH5
′
SfiI: 5
′
-AGTCTAACGTTCGGCCCAGCCGGCCTCGGGGGGCGACTTGGTCCAGCCGGGGGGG-3
′
scFv/Fab38 VH5
′
Sfi I:5
′
-AGTCTAACGTTCGGCCCAGCCGGCCTCGGGGGGAGGCGTGGTCCAGCCGGGGGGG-3
′
scFv/Fab35/38 VH3
′
linker:5
′
-GCCACCCGACCCACCACCGCCCGAGCCACCGCCACCTGGAGAGACGGTGACCGTTGTCCCTTG
GCC-3
′
scFv/Fab35/38 VL5
′
linker:5
′
-GGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCAGTGATGACCCAGTCTCCA-3
′
scFv/Fab35 VL3
′
Not I:5
′
-TGCTGCTGCGGCCGCTTTGATCTCCAGCTTGGTCCC-3
′
scFv/Fab38 VL3
′
Not I: 5
′
-TGCTGCTGCGGCCGCCGTGATCTCCAGCTTGGTCCC-3
′
Primers for scFv from Fab35/38 in orientation VL-VH
scFv/Fab35/38 VL5
′
Sfi I: 5
′
-ATGGCTCAGGGTTCGGCCCAGCCGGCCGTGATGACCCAGTCTCCA-3
′
scFv/Fab35 VL3
′
linker: 5
′
-GCCACCCGACCCACCACCGCCCGAGCCACCGCCACCTTTGATCTCCAGCTTGGTCCC-3
′
scFv/Fab38 VL3
′
linker:5
′
-GCCACCCGACCCACCACCGCCCGAGCCACCGCCACCCGTGATCTCCAGCTTGGTCCC-3
′
scFv/Fab35 VH5
′
linker: 5
′
-GGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCATCGGGGGGCGACTTGGTCCAGCCGG
GGGGG-3
′
scFv/Fab38 VH5
′
linker: 5
′
-GGCTCGGGCGGTGGTGGGTCGGGTGGCGGCGGATCATCGGGGGGAGGCGTGGTCCAGCCGG
GGGGG-3
′
scFv/Fab35/38 VH3
′
Not I: 5
′
-TGCTGCTGCGGCCGCTGGAGAGACGGTGACCGTTGTCCCTTGGCC-3
′
colonies used to inoculate 10 mL LB medium containing
50 μg/μL kanamycin. After 6–8 hours incubation at 26◦C,
5 mL was added to 50 mL Terrific Broth containing 0.5 mM
ZnCl, 50 μg/μL kanamycin, and shaken overnight at 26◦C.
After 14–16 hours, the 50 mL culture was used to inoculate
5 × 200 mL Terrific Broth supplemented as above and
incubated for further 3–5 hours at 26◦C. The broth was
supplemented to final concentrations of 0.5 M sorbitol,
4% NaCl, and 40 mM betain and allowed to stand for
30 minutes before protein synthesis was induced by IPTG
(final concentration 2 mM) and overnight shaking. After 20
hours, the bacteria were harvested by centrifugation (3700 g,
4◦C), lysed in 75 mM Tris.HCl (pH 9), 300 mM NaCl, 10%
glycerol, 5 mM DTT, 5 mM EDTA, sonicated and centrifuged
at 25000 g, 4◦C for 60 minutes. The supernatant was filtered,
desalted on an FPLC column at a flow rate of 6 mL/minute
(Amersham Biosciences, Heidelberg, Germany), and pooled
protein fractions were purified and eluted by nickel-NTA-
agarose chromatography (Qiagen, Hilden, Germany) using
75 mM Tris-HCl (pH 8.8), 10% glycerol, 1 M NaCl, and
0.5 M imidazol, at a flow rate of 2 mL/minute. Aliquots of
each fraction were separated by 10% SDS PAGE and proteins
were blotted onto nitrocellulose membranes as described
[63]. Fractions containing scFv35-ETA were pooled, con-
centrated by ultrafiltration, and purified by size exclusion
chromatography using a Bio-Prep SE-100/17 column (Bio-
Rad) on the Aekta purifier workstation (GE). Protein was
eluted with PBS (pH 7.4) and 1 M NaCl, analyzed by SDS-
PAGE, quantified by densitometry (GS-700 Imaging Den-
sitometer, Bio-Rad) after Coomassie staining in comparison
with BSA standards, and verified by the Bradford assay
(Bio-Rad).
4.3. Cell Lines and Cell Culture Reagents. Cell lines were
obtained from American Type Culture Collection (Embry-
onal rhabdomyosarcoma: TE-671, RD, A-204, histiocytic
lymphoma: U937), German Collection of Microorganisms,
and Cell Cultures (Alveolar rhabdomyosarcoma: RH-30) or
were provided by Ewa Koscielniak (Olgahospital, Stuttgart,
Germany; embryonal rhabdomyosarcoma: FL-OH-1, alve-
olar rhabdomyosarcoma: Ax-OH-1). All cell lines were
cultured in RPMI 1640 (Gibco Invitrogen, Carlsbad, USA)
supplemented with 10% bovine calf serum (Biochrom
AG, Berlin, Germany), 100 U/mL penicillin, and 100 μg/mL
streptomycin (Gibco Invitrogen).
4.4. Flow Cytometry. The cell-binding activity of scFv35-
ETA was evaluated by flow cytometry. Cell suspensions
containing 5 × 105 cells per mL were washed in PBS
incubated on ice with 1 μg scFv35-ETA protein diluted
in 100 μL PBS with 0.5% BSA. The cells were washed
again three times and treated with 100 μL of the anti-ETA
monoclonal antibody TC-1 [63] (1 : 100) for 30 minutes.
After three further washes, the cells were incubated with
PE-labeled antimouse immunoglobulin (1 : 50; Jackson
ImmunoReseacrch Europe Ltd, Suffolk, GB) for 30 minutes
at 4◦C. Finally, cells were washed three further times and
analyzed on a FACScalibur (Becton Dickinson, Heidelberg,
Germany).
4.5. Colorimetric XTT Cytotoxicity Assay. The cytotoxicity
assay was performed as described [64]. Briefly, 5 × 103 cell
per well was plated in 50 μL on 96-well plates and let it
attach for 3 hours at 37◦C. A serial dilution of scFv35-ETA
immunotoxin was applied in 50 μL aliquot resulting in a
final volume of 100 μL. Plates were checked for chromogen
development 72 hours after immunotoxin application by
adding 50 μL XTT/phenanzine methosulfate and further
incubation at 37◦C for 4 hours. Absorbance was measured
at 450 nm–630 nm as reference wave length. Colorimetric
XTT conversion was also used in a competitive approach.
Therefore, scFv35-ETA was added with a final constant
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concentration of 1.5 nM to varying concentrations (1–
100 molar excess) of scFv35.
4.6. Determination of IC50 Values. The concentration
required to achieve a 50% reduction of protein synthesis
(IC50) relative to untreated control cells was calculated using
GraphPad Prism 4. All measurements were performed in
triplicates.
4.7. Annexin V Apoptosis Assay. Induction of apoptosis was
measured by analysis of Ca2+-dependent binding of Annexin
V to phosphatidylserine on the cell surface of apoptotic cells
as described previously [33]. Briefly, 5 × 105 RD cells were
seeded in 12-well plates in 1 mL medium containing either
1 μg scFv35-ETA or phosphate buffered saline as control in
triplicates. Cells were harvested after 12, 14, and 48 hours
of incubation at 37◦C and incubated for 30 minutes on
ice with 500 μL supernatant of Annexin V-eGFP-expressing
HEK293T cells supplemented with 10 mM HEPES (pH 7.4),
150 mM NaCl, 5 mM KCl, and 2 mM CaCl2. After washing
in PBS twice, final measurements were performed under
the same buffer conditions with addition of 1 : 300 dilution
of Propidium Iodide (1 mg/mL) on a FACScalibur (Becton
Dickinson, Heidelberg, Germany).
4.8. Generation and Treatment of RMS in an In Vivo SCID
Mouse Model. SCID mice were injected subcutaneously with
5 × 106 RD cells suspended in DMEM serum-free culture
medium on day 1 of the experiment. On days 2–10, the mice
received twice daily intraperioneal injections of either 10 μg
scFv35-ETA (n = 6) or saline (n = 4), as described for other
toxins [62]. Tumor size was monitored transcutaneously on
days 4, 7, 10, 12, and 14 after inoculation of RD tumor cells
using a caliper. Tumor size was calculated according to the
formula: (length × width × height)/2.
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